PL3194405T4 - Makrocykliczne inhibitory kinazy lrrk2 - Google Patents
Makrocykliczne inhibitory kinazy lrrk2Info
- Publication number
- PL3194405T4 PL3194405T4 PL15766801T PL15766801T PL3194405T4 PL 3194405 T4 PL3194405 T4 PL 3194405T4 PL 15766801 T PL15766801 T PL 15766801T PL 15766801 T PL15766801 T PL 15766801T PL 3194405 T4 PL3194405 T4 PL 3194405T4
- Authority
- PL
- Poland
- Prior art keywords
- kinase inhibitors
- lrrk2 kinase
- macrocyclic
- macrocyclic lrrk2
- inhibitors
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14290279 | 2014-09-17 | ||
| EP15766801.3A EP3194405B1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic lrrk2 kinase inhibitors |
| PCT/EP2015/071349 WO2016042089A1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic lrrk2 kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL3194405T3 PL3194405T3 (pl) | 2019-07-31 |
| PL3194405T4 true PL3194405T4 (pl) | 2019-07-31 |
Family
ID=51752058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15766801T PL3194405T4 (pl) | 2014-09-17 | 2015-09-17 | Makrocykliczne inhibitory kinazy lrrk2 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10377772B2 (pl) |
| EP (1) | EP3194405B1 (pl) |
| JP (1) | JP2017529365A (pl) |
| KR (1) | KR20170048599A (pl) |
| CN (1) | CN107108641A (pl) |
| AU (1) | AU2015316801B2 (pl) |
| BR (1) | BR112017005299A2 (pl) |
| CA (1) | CA2960777A1 (pl) |
| DK (1) | DK3194405T3 (pl) |
| EA (1) | EA032838B1 (pl) |
| ES (1) | ES2717510T3 (pl) |
| HU (1) | HUE043972T2 (pl) |
| IL (1) | IL251054B (pl) |
| MX (1) | MX2017003470A (pl) |
| PL (1) | PL3194405T4 (pl) |
| SG (1) | SG11201701936WA (pl) |
| TR (1) | TR201904514T4 (pl) |
| TW (1) | TW201625639A (pl) |
| WO (1) | WO2016042089A1 (pl) |
| ZA (1) | ZA201701841B (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111221514B (zh) * | 2020-01-13 | 2023-03-03 | 陕西心像信息科技有限公司 | 基于OsgEarth的三维可视化组件实现方法及系统 |
| MX2022009285A (es) * | 2020-01-31 | 2022-11-09 | Oncodesign Prec Medicine Opm | Inhibidores macrocíclicos de la quinasa rip2. |
| KR20230006560A (ko) | 2020-05-06 | 2023-01-10 | 르 라보레또레 쎄르비에르 | 새로운 거대고리 lrrk2 키나제 억제제 |
| BR112023017834A2 (pt) | 2021-03-18 | 2023-10-03 | Servier Lab | Inibidores de lrrk2 cinase macrocíclicos |
| WO2023064768A1 (en) * | 2021-10-11 | 2023-04-20 | Baylor College Of Medicine | G-protein-coupled receptor regulators and methods of use thereof |
| TW202330549A (zh) | 2021-10-27 | 2023-08-01 | 丹麥商Ｈ 朗德貝克公司 | Lrrk2抑制劑 |
| WO2023222005A1 (zh) * | 2022-05-18 | 2023-11-23 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其中间体、药物组合物和用途 |
| TW202412777A (zh) * | 2022-09-15 | 2024-04-01 | 丹麥商Ｈ 朗德貝克公司 | 富白胺酸重複激酶2（lrrk2）抑制劑 |
| AR132486A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| WO2024218288A1 (en) * | 2023-04-20 | 2024-10-24 | H. Lundbeck A/S | Leucine-rich repeat kinase 2 (lrrk2) inhibitors |
| AR132488A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| WO2024218296A1 (en) * | 2023-04-20 | 2024-10-24 | H. Lundbeck A/S | Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| EG20677A (en) | 1993-10-01 | 1999-11-30 | Astra Ag | Method and an apparatus for micronizing the particle size |
| EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| ATE375344T1 (de) | 1996-07-24 | 2007-10-15 | Bristol Myers Squibb Pharma Co | Azolotriazine und pyrimidine |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| HUP0303653A3 (en) | 2000-12-28 | 2006-05-29 | Ono Pharmaceutical Co | Tricyclic and heterocyclic derivative and pharmaceutical compositions containing them as the active ingredient |
| JP2005505506A (ja) * | 2001-06-12 | 2005-02-24 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病の治療に有用な大環状分子 |
| EP2316927B1 (en) | 2004-10-21 | 2014-11-05 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Kaspp (lrrk2) gene, its production and use for the detection and treatment of neurodegenerative disorders |
| NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
| FI123725B (fi) | 2005-08-01 | 2013-10-15 | Reijo Viljanen | Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet |
| TWI525096B (zh) | 2005-11-16 | 2016-03-11 | Ｃｔｉ生技製藥有限公司 | 氧連接之嘧啶衍生物 |
| WO2009127642A2 (en) | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| EA021437B1 (ru) | 2009-09-29 | 2015-06-30 | Глэксо Груп Лимитед | Соединения, ингибирующие lrrk2 киназную активность |
| CN105693720B (zh) * | 2010-05-20 | 2019-01-18 | 阵列生物制药公司 | 作为trk激酶抑制剂的大环化合物 |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| US9090630B2 (en) * | 2011-09-30 | 2015-07-28 | Oncodesign S.A. | Macrocyclic FLT3 kinase inhibitors |
| MX342177B (es) * | 2011-09-30 | 2016-09-20 | Ipsen Pharma Sas | Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica. |
-
2015
- 2015-09-17 CA CA2960777A patent/CA2960777A1/en not_active Abandoned
- 2015-09-17 JP JP2017515823A patent/JP2017529365A/ja active Pending
- 2015-09-17 HU HUE15766801A patent/HUE043972T2/hu unknown
- 2015-09-17 MX MX2017003470A patent/MX2017003470A/es unknown
- 2015-09-17 SG SG11201701936WA patent/SG11201701936WA/en unknown
- 2015-09-17 US US15/511,879 patent/US10377772B2/en not_active Expired - Fee Related
- 2015-09-17 ES ES15766801T patent/ES2717510T3/es active Active
- 2015-09-17 TW TW104130753A patent/TW201625639A/zh unknown
- 2015-09-17 WO PCT/EP2015/071349 patent/WO2016042089A1/en not_active Ceased
- 2015-09-17 PL PL15766801T patent/PL3194405T4/pl unknown
- 2015-09-17 DK DK15766801.3T patent/DK3194405T3/en active
- 2015-09-17 AU AU2015316801A patent/AU2015316801B2/en not_active Ceased
- 2015-09-17 CN CN201580061216.1A patent/CN107108641A/zh active Pending
- 2015-09-17 BR BR112017005299A patent/BR112017005299A2/pt not_active IP Right Cessation
- 2015-09-17 TR TR2019/04514T patent/TR201904514T4/tr unknown
- 2015-09-17 EP EP15766801.3A patent/EP3194405B1/en not_active Not-in-force
- 2015-09-17 EA EA201790626A patent/EA032838B1/ru not_active IP Right Cessation
- 2015-09-17 KR KR1020177010322A patent/KR20170048599A/ko not_active Withdrawn
-
2017
- 2017-03-09 IL IL251054A patent/IL251054B/en not_active IP Right Cessation
- 2017-03-15 ZA ZA2017/01841A patent/ZA201701841B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017005299A2 (pt) | 2017-12-12 |
| AU2015316801B2 (en) | 2019-03-07 |
| EP3194405A1 (en) | 2017-07-26 |
| KR20170048599A (ko) | 2017-05-08 |
| MX2017003470A (es) | 2017-08-07 |
| US10377772B2 (en) | 2019-08-13 |
| US20170240565A1 (en) | 2017-08-24 |
| IL251054B (en) | 2019-03-31 |
| SG11201701936WA (en) | 2017-04-27 |
| HUE043972T2 (hu) | 2019-09-30 |
| ES2717510T3 (es) | 2019-06-21 |
| EA032838B1 (ru) | 2019-07-31 |
| JP2017529365A (ja) | 2017-10-05 |
| PL3194405T3 (pl) | 2019-07-31 |
| TW201625639A (zh) | 2016-07-16 |
| ZA201701841B (en) | 2019-08-28 |
| CN107108641A (zh) | 2017-08-29 |
| IL251054A0 (en) | 2017-04-30 |
| TR201904514T4 (tr) | 2019-04-22 |
| EP3194405B1 (en) | 2018-12-26 |
| CA2960777A1 (en) | 2016-03-24 |
| DK3194405T3 (en) | 2019-04-15 |
| WO2016042089A1 (en) | 2016-03-24 |
| AU2015316801A1 (en) | 2017-04-27 |
| EA201790626A1 (ru) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| ZA201901034B (en) | Macrocycle kinase inhibitors | |
| EP3172213A4 (en) | Macrocyclic kinase inhibitors and uses thereof | |
| IL248086B (en) | Biaryl kinase inhibitors | |
| EP3131900A4 (en) | Heterocyclic kinase inhibitors | |
| ZA201701841B (en) | Macrocyclic lrrk2 kinase inhibitors | |
| IL251784A0 (en) | Bromodomain inhibitors | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| GB201615282D0 (en) | Tankyrase inhibitors | |
| ZA201506327B (en) | Macrocyclic lrrk2 kinase inhibitors | |
| SG11201609350XA (en) | Methods for inhibiting necroptosis | |
| IL258438B (en) | 2-Aminoquinoline derivatives as p70s6 kinase inhibitors | |
| ZA201701331B (en) | Macrocyclic rip2 kinase inhibitors | |
| EP3201181A4 (en) | Sphingosine kinase inhibitors | |
| GB201414116D0 (en) | Benzodiazepine derivatives | |
| GB201404555D0 (en) | Macrocyclic kinase inhibitors | |
| GB201404570D0 (en) | Macrocyclic kinase inhibitors | |
| GB201519382D0 (en) | Kinase inhibitors | |
| GB201519381D0 (en) | Kinase inhibitors | |
| GB201614783D0 (en) | Kinases inhibitors | |
| AU2014903812A0 (en) | Novel kinase inhibitors i | |
| GB201418154D0 (en) | Inhibitors | |
| GB201409661D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201405532D0 (en) | Novel compounds and their use as Kinase inhibitors |